Table 3.
Univariate analysis of factors contributing to an SVR in elderly patients (n = 108)
| Risk factor | SVR (n = 54) | non SVR (n = 54) | P value |
|---|---|---|---|
| Gender (male/female) | 33/21 | 21/33 | 0.021 |
| HCV genotype, (1/2) | 35/19 | 51/3 | < 0.001 |
| Previous IFN therapy, (yes/no) | 16/38 | 24/30 | 0.163 |
| Diabetes mellitus, (yes/no) | 7/47 | 12/42 | 0.312 |
| Hypertension, (yes/no) | 22/32 | 25/29 | 0.698 |
| Body mass index (kg/m2), mean ± SD | 23.0 ± 3.0 | 23.7 ± 3.0 | 0.212 |
| White blood cells (/mm3), mean ± SD | 4948 ± 1412 | 4869 ± 1260 | 0.761 |
| Hemoglobin (g/dL), mean ± SD | 13.9 ± 1.2 | 13.8 ± 1.2 | 0.583 |
| Platelets (× 104/mm3), mean ± SD | 16.4 ± 4.2 | 14.2 ± 3.3 | 0.003 |
| AST (IU/L), mean ± SD | 69.1 ± 44.0 | 61.3 ± 29.2 | 0.280 |
| ALT (IU/L), mean ± SD | 86.9 ± 80.7 | 65.1 ± 43.7 | 0.084 |
| AFP (ng/ml), mean ± SD | 12.1 ± 19.6 | 19.4 ± 39.7 | 0.228 |
| Fibrosis score, (F1,2/F3,4) | 36/18 | 27/27 | 0.079 |
| Serum HCV RNA (KIU/ml), mean ± SD | 1290 ± 1441 | 1343 ± 1265 | 0.838 |
| Peg-IFN does (μg/kg week), mean ± SD | 1.23 ± 0.31 | 1.21 ± 0.30 | 0.494 |
| Daily ribavirin dose (mg/kg), mean ± SD | 9.68 ± 2.96 | 9.48 ± 2.92 | 0.268 |
| 80/80/80 adherence, (yes/no) | 27/27 | 20/34 | 0.244 |
| rapid virological response, (yes/no) | 24/30 | 0/54 | < 0.001 |
| early virological response, (yes/no) | 47/7 | 14/40 | < 0.001 |
Data are shown as absolute values or mean ± standard deviation. AST aspartate aminotransferase; ALT alanine aminotransferase; AFP alpha-fetoprotein; HCV hepatitis C virus; Peg-IFN pegylated interferon; SVR sustained virological response